Analysis Tools
neoplasm
|
• at 1 week or 1 month of induction with doxycycline, mutants do not exhibit formation of lung tumors and lung histology remains normal
|
|
Allele Symbol Allele Name Allele ID |
Tg(tetO-Fgf9,-EGFP)#Dor transgene insertion, David M Ornitz MGI:5538516 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 1 week or 1 month of induction with doxycycline, mutants do not exhibit formation of lung tumors and lung histology remains normal
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 2 of 5 mutants that develop ascites after 4 months of doxycycline induction contain cells with malignant cytology
|
|
• doxycycline induction from E16.5 to E18.5 results in lung mesenchymal hyperplasia beneath a benign-appearing Nkx2.1 positive epithelium with histological features of Type I or cystic pleuropulmonary blastoma
|
|
• one day following doxycycline administration, adult mutants exhibit formation of small nodules (epithelial clusters) on the lung surface
• papillary adenoma and papillary adenocarcinoma develop in mice treated with doxycycline for 4 and 8 days, respectively
• small tumor nodules and large tumor nodules persist in the lungs of mutants treated with doxycycline for 2-4 days followed by 1 month of doxycycline and in mutants treated with doxycycline for 2 weeks followed by 9 and 18 weeks of withdrawal, respectively
|
|
• after 4 days of doxycycline induction, nodules are histologically consistent with papillary adenoma
|
|
• after 8 days of doxycycline induction, the cells forming papillary structures become atypical with larger and hyperchromatic nuclei, consistent with papillary adenocarcinoma
|
|
• lungs show increased mesenchymal proliferation after doxycycline induction from E10.5 to E12.5
|
|
• doxycycline treated adults show a median survival of 89 days and die due to respiratory failure
|
|
• lungs show increased mesenchymal proliferation after doxycycline induction from E10.5 to E12.5
|
|
• one day following doxycycline administration, adult mutants exhibit formation of small nodules (epithelial clusters) on the lung surface
• papillary adenoma and papillary adenocarcinoma develop in mice treated with doxycycline for 4 and 8 days, respectively
• small tumor nodules and large tumor nodules persist in the lungs of mutants treated with doxycycline for 2-4 days followed by 1 month of doxycycline and in mutants treated with doxycycline for 2 weeks followed by 9 and 18 weeks of withdrawal, respectively
|
|
• after 4 days of doxycycline induction, nodules are histologically consistent with papillary adenoma
|
|
• after 8 days of doxycycline induction, the cells forming papillary structures become atypical with larger and hyperchromatic nuclei, consistent with papillary adenocarcinoma
|
|
• lungs exhibit reduced branching after doxycycline induction from E10.5 to E12.5
|
|
• lungs exhibit expanded mesenchyme after doxycycline induction from E10.5 to E12.5
|
|
• lungs exhibit dilated epithelial ducts after doxycycline induction from E10.5 to E12.5
|
|
• doxycycline treated adults die due to respiratory failure
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| lung cancer | DOID:1324 |
OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 |
J:204282 | |
| pleuropulmonary blastoma | DOID:4769 | J:224791 | ||
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• doxycycline treated embryos exhibit an extended domain of blood vessels into the expanded lung mesenchyme at E13.5
|
|
• beginning at E12.5, doxycycline treated embryos exhibit enlarged lung size
|
|
• doxycycline treated embryos exhibit increased luminal space, fewer epithelial airways and a wide band of mesenchyme separating epithelial ducts at E14.5
|
|
• doxycycline treated embryos exhibit a reduction in epithelial branching at E11.5 and E12.5
• beginning at E12.5, doxycycline treated embryos exhibit an arrest in branching and luminal dilation
|
|
• doxycycline treated embryos exhibit a large mesenchymal expansion in the lungs at E11.5 and E12.5
|
|
• doxycycline treated embryos show an absence of smooth muscle in the sub-epithelial compartment of lungs at E14.5, although it is present surrounding large blood vessels
|
|
• doxycycline treated embryos exhibit an extended domain of blood vessels into the expanded lung mesenchyme at E13.5
|
|
• beginning at E12.5, doxycycline treated embryos exhibit enlarged lung size
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/30/2024 MGI 6.23 |
|
|
|
||